In this group of well-characterized genetic FTLD patients, established CSF biomarkers for AD diagnosis (τT, τP-181, Aβ42 and Aβ40) and a novel emerging (TDP-43) biomarker were analyzed. The gene discussed is TARDBP; the disease is Alzheimer disease.